COMPARATIVE CHARACTERISTICS OF RENAL BLOOD FLOW IN PATIENTS WITH CHRONIC RENAL FAILURE DEVELOPED AS A RESULT OF MYELOMA NEPHROPATHY AND IN PRIMARY NEPHROLOGY PATHOLOGY
Abstract and keywords
Abstract (English):
A comparative analysis of the indicators of renal hemodynamics in patients with chronic renal failure/chronic kidney disease (CRF/CKD) developed against myeloma nephropathy (group 1) and with primary kidney disease (group 2) was done. 20 patients were included in the first group, 14 patients were in the second one, and in most cases there was Stage 3 CRF/CKD. There were analyzed the following indicators of renal blood flow: peak systolic velocity, end diastolic velocity, mean flow velocity throughout the entire cardiac cycle, resistive index and pulsation index. Circulation figures were recorded at the level of basic, segmental, interlobar, arc, interlobular renal arteries. It is concluded that violations of renal blood flow and vascular resistance in patients with multiple myeloma complicated by chronic renal failure are primarily due to CKD itself. The differences in the two groups of patients with CRF/CKD were only about the average level in the parenchymal blood flow velocity (interlobular, arcuate, interlobar arteries); at myeloma nephropathy it was significantly reduced in comparison with the control group and patients with CRF/CKD without hemoblastosis. The rest velocity parameters were significantly reduced and vascular resistance indices were increased in comparison with the control and did not differ in groups of patients with CRF/CKD. Thus, hemodynamic changes at the level of parenchyma are the most important for patients with multiple myeloma, which suggests more severe violations of kidneys in these patients with the complication of CRF.

Keywords:
chronic kidney disease, myeloma nephropathy, renal hemodynamics.
References

1. Bessmelʹtsev S.S., Abdulkadyrov K.M. Multiple myeloma. St. Petersburg: Dialekt; 2004 (in Russian).

2. Brenner B.M. Mechanisms of progression of kidney disease. Nefrologiya 1999; 3(4):23-27 (in Russian).

3. Voytsekhovskiy V.V., Landyshev Yu.S. Modern aspects of diagnosis and treatment of multiple myeloma. Novye Sankt-Peterburgskie vrachebnye vedomosti 2006; 4:18-22 (in Russian).

4. Voitsekhovskiy V.V., Landishev U.S., Grigorenko A.A., Tkacheva S.I., Kalenbet L.I., Goborov N.D. Endobronchial microhemocirculation disorders in patients with multiple myeloma. Dal´nevostochnyy meditsinskiy zhurnal 2010; 2:30-33 (in Russian).

5. Voytsekhovskiy V.V., Gruzdova A.V., Filatova E.A., Goborov N.D., Makarova N.V., Sinyuk A.A., Kondrakhina A.P. The analysis of infectious complications of hemoblastosis in the Amur region. Bûlleten´ fiziologii i patologii dyhaniâ 2012; 46:64-68 (in Russian).

6. Glazun L.O., Polukhina E.V. Ultrasound diagnosis of kidney disease. Moscow: Vidar-M; 2014 (in Russian).

7. Glazun L.O., Polukhina E.V. Renal vessels ultrasound. Khabarovsk; 2003 (in Russian).

8. Makarova N.V. Features of renal hemodynamics in patients with multiple myeloma. Amurskiy meditsinskiy zhurnal 2014; 1(5):54-60 (in Russian).

9. Makarova N.V. Features of renal blood flow in patients with multiple myeloma at different stages of tumor progression. Bûlleten´ fiziologii i patologii dyhaniâ 2016; 61: 52-59 (in Russian).

10. Nikolaev A.Yu. Chronic renal failure: clinical features, diagnosis and treatment. Russkiy meditsinskiy zhurnal. 2000; 3:138-142 (in Russian).

11. Rukavitsyn O.A, editor. Hematology. National guidelines. Moscow: GEOTAR Media; 2015 (in Russian).

12. Salogub G.N., Stepanova N.V., Podgayetskaya O.J. Kidney involvement in multiple myeloma. Gematologiya i transfuziologiya 2010; 55(3):25-33 (in Russian).

13. Durie B.G., Salmon S.E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36(3):842-854.

14. Sengul S., Zwizinski C., Simon E.E., Kapasi A., Singhal P.C., Batuman V. Endocytosis of light chains induces cytokines through activation on NK-κB in human proximal tubule cells. Kidney Int. 2002; 62(6):1977-1988.

15. Sengul S., Zwizinski C., Batuman V. Role of MARK pathways in light chain-induced cytokine production in human proximal tubule cells. Am. J. Physiol. Renal Physiol. 2003; 284(6):F1245-F1254.

16. Wada T., Yokoyama H., Kobayasbi K. Chemokines new target molecules in renal diseases. Clin. Exp. Nephrol. 2000; 4:273-280.

Login or Create
* Forgot password?